Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:497
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [41] Improvement of solubility and refolding of an anti-human epidermal growth factor receptor 2 single-chain antibody fragment inclusion bodies
    Salehinia, Javad
    Sadeghi, Hamid Mir Mohammad
    Abedi, Daryoush
    Akbari, Vajihe
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2018, 13 (06) : 566 - 574
  • [42] Human epidermal growth factor receptor 2 testing recommendation - In reply
    Wolff, Antonio C.
    Hammond, M. Elizabeth H.
    Schwartz, Jared N.
    Hayes, Daniel F.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1331 - 1333
  • [43] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4020 - 4020
  • [44] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1330 - 1330
  • [45] Human epidermal growth factor receptor 2 testing recommendation - In reply
    Wolff, Antonio C.
    Hammond, M. Elizabeth H.
    Schwartz, Jared N.
    Hayes, Daniel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4021 - 4023
  • [46] Targeting the Human Epidermal Growth Factor Receptor 2 in Esophageal Cancer
    Almhanna, Khaldoun
    Meredith, Kenneth L.
    Hoffe, Sarah E.
    Shridhar, Ravi
    Coppola, Domenico
    CANCER CONTROL, 2013, 20 (02) : 111 - 116
  • [47] Accurate Assessment of Human Epidermal Growth Factor Receptor 2 Reply
    Bhargava, Rohit
    Tubbs, Raymond R.
    Mohsin, Syed K.
    Dabbs, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1728 - 1729
  • [48] Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?
    De, Pradip
    Smith, Brian R.
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4289 - 4292
  • [49] Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway
    Amishima, M
    Munakata, M
    Nasuhara, Y
    Sato, A
    Takahashi, T
    Homma, Y
    Kawakami, Y
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) : 1907 - 1912
  • [50] A MONOCLONAL-ANTIBODY TO THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR
    WATERFIELD, MD
    MAYES, ELV
    STROOBANT, P
    BENNET, PLP
    YOUNG, S
    GOODFELLOW, PN
    BANTING, GS
    OZANNE, B
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1982, 20 (02) : 149 - 161